HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program

Journal of Clinical Virology

Volumn 60, Issue 3, 2014, Pages 250-256

  Tabrizi, Sepehr N ^a,b,e   Brotherton, Julia M L ^a,c,d   Stevens, Matthew P ^a,b   Condon, John R ^f   McIntyre, Peter ^d   Smith, David ^g   Garland, Suzanne M ^a,b,e  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c VICTORIAN CYTOLOGY SERVICE   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cervical Cancer; Cervical cytology; CIN; Genotype; Human papillomavirus; Linear array

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; FEMALE; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 53; HUMAN PAPILLOMAVIRUS TYPE 62; HUMAN PAPILLOMAVIRUS TYPE 89; HUMAN TISSUE; INDIGENOUS AUSTRALIAN; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; UTERINE CERVIX CYTOLOGY; VACCINATION; VAGINA SMEAR KIT; WART VIRUS; AGE; ALPHAPAPILLOMAVIRUS; CROSS-SECTIONAL STUDY; GENETICS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PREVENTIVE HEALTH SERVICE; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX; VAGINA SMEAR; VIROLOGY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; ALPHAPAPILLOMAVIRUS; AUSTRALIA; CERVIX UTERI; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HUMANS; IMMUNIZATION PROGRAMS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; UTERINE CERVICAL NEOPLASMS; VACCINATION; VAGINAL SMEARS; YOUNG ADULT;

EID: 84902126358     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.04.013     Document Type: Article

References (33)

1. GLOBOCAN Section of Cancer Information, 2008. Available from: [updated 2008; cited 22.07.11]. http://globocan.iarc.fr/factsheets/populations/factsheet.asp%3Funo=900.
2. Papachristou E., Sypsa V., Paraskevis D., Gkekas A., Politi E., Nicolaidou E., et al. Prevalence of different HPV types and estimation of prognostic risk factors based on the linear array HPV genotyping test. J Med Virol 2009, 81(12):2059-2065.
3. Kitchener H.C., Castle P.E., Cox J.T. Achievements and limitations of cervical cytology screening. Vaccine 2006, 24(Suppl. 3:S3):63-70. [Chapter 7].
4. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55(4):244-265.
5. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) study group. J Natl Cancer Inst 1995, 87(11):796-802.
6. Schiffman M.H., Bauer H.M., Hoover R.N., Glass A.G., Cadell D.M., Rush B.B., et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993, 85(12):958-964.
7. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
8. de Sanjose S., Diaz M., Castellsague X., Clifford G., Bruni L., Munoz N., et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007, 7(7):453-459.
9. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., zur Hausen H. Classification of papillomaviruses. Virology 2004, 324(1):17-27.
10. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348(6):518-527.
11. Lu B., Kumar A., Castellsague X., Giuliano A.R. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review and meta-analysis. BMC Infect Dis 2011, 11:13.
12. Gertig D.M., Brotherton J.M., Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2011, 8(2):171-178.
13. Brestovac B., Harnett G.B., Smith D.W., Shellam G.R., Frost F.A. Human papillomavirus genotypes and their association with cervical neoplasia in a cohort of Western Australian women. J Med Virol 2005, 76(1):106-110.
14. Chen S., O'Sullivan H., Tabrizi S.N., Fairley C.K., Quinn M.A., Garland S.M. Prevalence and genotyping of HPV in cervical cancer among Australian women. Int J Gynaecol Obstet 1999, 67(3):163-168.
15. O'Keefe E.J., Gardner A., Currie M.J., Garland S., Tabrizi S., Bowden F.J. Prevalence of genital human papillomavirus DNA in a sample of senior school-aged women in the Australian Capital Territory. Sex Health 2006, 3(2):91-94.
16. Stevens M.P., Garland S.M., Tan J.H., Quinn M.A., Petersen R.W., Tabrizi S.N. HPV genotype prevalence in women with abnormal pap smears in Melbourne, Australia. J Med Virol 2009, 81(7):1283-1291.
17. Stevens M.P., Tabrizi S.N., Quinn M.A., Garland S.M. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia. Int J Gynecol Cancer 2006, 16(3):1017-1024.
18. Garland S.M., Brotherton J.M., Condon J.R., McIntyre P.B., Stevens M.P., Smith D.W., et al. Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med 2011, 9(1):104.
19. Stevens M.P., Garland S.M., Rudland E., Tan J., Quinn M.A., Tabrizi S.N. Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J Clin Microbiol 2007, 45(7):2130-2137.
20. Stevens M.P., Rudland E., Garland S.M., Tabrizi S.N. Assessment of MagNA pure LC extraction system for detection of human papillomavirus (HPV) DNA in PreservCyt samples by the Roche AMPLICOR and LINEAR ARRAY HPV tests. J Clin Microbiol 2006, 44(7):2428-2433.
21. Layton-Henry J., Scurry J., Planner R., Allen D., Sykes P., Garland S.M., et al. Cervical adenoid basal carcinoma, five cases and literature review. Int J Gynecol Cancer 1996, 6(3):193-199.
22. Stevens M.P., Garland S.M., Tabrizi S.N. Human papillomavirus genotyping using a modified linear array detection protocol. J Virol Methods 2006, 135(1):124-126.
23. Stevens M.P., Garland S.M., Tabrizi S.N. Validation of an automated detection platform for use with the Roche linear array human papillomavirus genotyping test. J Clin Microbiol 2008, 46(11):3813-3816.
24. Bruni L., Diaz M., Castellsague X., Ferrer E., Bosch F.X., de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010, 202(12):1789-1799.
25. Smith J.S., Melendy A., Rana R.K., Pimenta J.M. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008, 43(Suppl. 4):S5-S25. S25.e1-41.
26. Clifford G.M., Rana R.K., Franceschi S., Smith J.S., Gough G., Pimenta J.M. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005, 14(5):1157-1164.
27. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121(3):621-632.
28. Baandrup L., Munk C., Andersen K.K., Junge J., Iftner T., Kjaer S.K. HPV16 is associated with younger age in women with cervical intraepithelial neoplasia grade 2 and 3. Gynecol Oncol 2011, 124(2):281-285.
29. Brotherton J.M., Tabrizi S.N., Garland S.M. Does HPV type 16 or 18 prevalence in cervical intraepithelial neoplasia grade 3 lesions vary by age? An important issue for postvaccination surveillance. Future Microbiol 2012, 7(2):193-199.
30. Australian Institute of Health and Welfare Cervical screening in Australia 2010-2011. Cancer series 2013, 76. AIHW, Canberra, [Cat. No. CAN 72].
31. Ripabelli G., Grasso G.M., Del Riccio I., Tamburro M., Sammarco M.L. Prevalence and genotype identification of human papillomavirus in women undergoing voluntary cervical cancer screening in Molise, central Italy. Cancer Epidemiol 2010, 34(2):162-167.
32. Tabrizi S.N., Brotherton J.M., Kaldor J.M., Skinner S.R., Cummins E., Liu B., et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012, 206(11):1645-1651.
33. Guan P., Howell-Jones R., Li N., Bruni L., de Sanjose S., Franceschi S., et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012, 131(10):2349-2359.